Emboline, Inc. appears in FDA records as the applicant for a single 510(k) premarket notification in the retrieved collection: K261715, for the Emboliner Embolic Protection System (EPC-03). The filing carries product code PUM, device class 2, regulation number 870.1251, and the classification name Temporary Catheter, Embolic Protection, Transcatheter Intracardiac Procedures, with a Cardiovascular advisory committee. The record lists a decision date of September 8, 2026 and a decision description of Substantially Equivalent. The company’s own product page states the same clearance date and that the system is available for sale in the United States. [1][4][6]

The documented device and its components

Emboline’s product page describes the Emboliner Embolic Protection Catheter as a double-wall, cylindrical Nitinol mesh filter with an integrated self-sealing access port through which a TAVR delivery system passes. The same page frames the design around aortic coverage and capture of debris liberated by transcatheter heart procedures. The company homepage describes the Emboliner Full-Body Embolic Protection System as used during interventional heart procedures to capture and remove embolic debris released into the bloodstream. These are manufacturer descriptions of device design and intended use context, not independently verified performance data. [6][7]

The EPC-03 instructions for use, published by Emboline as LBL-0618, identify the product as the Emboliner Embolic Protection System and mark it Rx only, with federal law restricting sale to or on the order of a physician. The labeling states contents are supplied sterile using an irradiation process, are for single patient use only, and must not be reused, reprocessed, or re-sterilized. It also lists storage in a cool, dry place and non-pyrogenic status. The document carries a release date of 02NOV2026 under Ver. G. [2]

The same labeling includes a symbol legend covering maximum recommended guidewire, maximum guidewire diameter, rated burst pressure, nominal inflation pressure, minimum inside diameter of a compatible introducer sheath, contents of packaging, and a statement that the device does not contain DEHP. It also lists manufacturer contact details for Emboline, Inc. at 2901 Mission Street, Building 2, Santa Cruz, CA 95060. An earlier revision, Ver. F, carries a release date of 21SEP2026 and the same manufacturer block. [2][3]

Regulatory record and filing scope

The FDA 510(k) database entry for K261715 names Emboline, Inc. as applicant at 2901 Mission St., Bldg. 2, Santa Cruz, CA 95060, with Will Michul listed as contact. The record shows date received May 22, 2026, decision date September 8, 2026, decision code SESE, clearance type Traditional, third-party review flag N, and a summary statement. The advisory committee is listed as CV, and the openFDA fields associate the product code with a Cardiovascular medical specialty. [1]

The FDA premarket notification page for the same number repeats the device classification name, 510(k) number, device name, and applicant identity. In the retrieved collection, the 510(k) pathway holds one linked record and the decision count is one SESE; the record sample likewise contains one entry, K261715. These counts describe the retrieved filings as of the snapshot and are not measures of total company sales, total portfolio, or safety performance. No recall records appear in the retrieved sample. [1][4]

Published clinical program context

Emboline’s clinical results page states that in October 2025 the company completed enrollment in the Protect the Head to Head IDE trial, identified as NCT05684146, described there as a 500-patient, prospective, randomized, open-label, multicenter, two-arm study comparing the Emboliner Embolic Protection Catheter with a control device, the Sentinel CPS from Boston Scientific, in patients undergoing TAVR. These are the manufacturer’s statements about trial design and enrollment status; results are not reported in the retrieved material. [9]

Identity and attribution boundaries

The FDA records identify Emboline, Inc. as the legal applicant for K261715; no parent company, brand owner, or corporate affiliate is verified in the retrieved sources. The Santa Cruz address appears in both the FDA filing and the manufacturer’s labeling and contact page, but the retrieved material does not establish a headquarters designation beyond those published addresses. Product names such as Emboliner and EPC-03 are used as they appear in the FDA record and the manufacturer’s documentation. [1][2][8]

Statements about device design, intended debris capture, trial enrollment, and U.S. availability originate with Emboline’s published pages and labeling, while clearance details originate with FDA records. The retrieved sources do not include clinical outcome results, independent testing reports, certifications, or customer lists, so those points remain unknown here. [2][6][9]